Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2000 Mar;37(3):182–185. doi: 10.1136/jmg.37.3.182

Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland

S McIlroy 1, V Crawford 1, K Dynan 1, B McGleenon 1, M Vahidassr 1, J Lawson 1, A Passmore 1
PMCID: PMC1734550  PMID: 10699053

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that has been associated, sometimes controversially, with polymorphisms in a number of genes. Recently the butyrylcholinesterase K variant (BCHE K) allele has been shown to act in synergy with the apolipoprotein E ε4 (APOE ε4) allele to promote risk for AD. Most subsequent replicative studies have been unable to confirm these findings. We have conducted a case-control association study using a clinically well defined group of late onset AD patients (n=175) and age and sex matched control subjects (n=187) from the relatively genetically homogeneous Northern Ireland population to test this association. The BCHE genotypes of patients were found to be significantly different from controls (χ2=23.68, df=2, p<<0.001). The frequency of the K variant allele was also found to differ significantly in cases compared to controls (χ2=16.39, df=1, p<<0.001) leading to an increased risk of AD in subjects with this allele (OR=3.50, 95% CI 2.20-6.07). This risk increased in subjects 75 years and older (OR=5.50, 95% CI 2.56-11.87). At the same time the APOE ε4 associated risk was found to decrease from 6.70 (95% CI 2.40-19.04) in 65-74 year olds to 3.05 (95% CI 1.34-6.95) in those subjects 75 years and older. However, we detected no evidence of synergy between BCHE K and APOE ε4. The results from this study suggest that possession of the BCHE K allele constitutes a significant risk for AD in the Northern Ireland population and, furthermore, this risk increases with increasing age.


Keywords: Alzheimer's disease; BCHE K; APOE

Full Text

The Full Text of this article is available as a PDF (134.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartels C. F., Jensen F. S., Lockridge O., van der Spek A. F., Rubinstein H. M., Lubrano T., La Du B. N. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet. 1992 May;50(5):1086–1103. [PMC free article] [PubMed] [Google Scholar]
  2. Blacker D., Haines J. L., Rodes L., Terwedow H., Go R. C., Harrell L. E., Perry R. T., Bassett S. S., Chase G., Meyers D. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology. 1997 Jan;48(1):139–147. doi: 10.1212/wnl.48.1.139. [DOI] [PubMed] [Google Scholar]
  3. Brindle N., Song Y., Rogaeva E., Premkumar S., Levesque G., Yu G., Ikeda M., Nishimura M., Paterson A., Sorbi S. Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease. Hum Mol Genet. 1998 May;7(5):933–935. doi: 10.1093/hmg/7.5.933. [DOI] [PubMed] [Google Scholar]
  4. Crawford F., Fallin D., Suo Z., Abdullah L., Gold M., Gauntlett A., Duara R., Mullan M. The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations. Neurosci Lett. 1998 Jun 19;249(2-3):115–118. doi: 10.1016/s0304-3940(98)00423-6. [DOI] [PubMed] [Google Scholar]
  5. Crook R., Hardy J., Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods. 1994 Aug;53(2):125–127. doi: 10.1016/0165-0270(94)90168-6. [DOI] [PubMed] [Google Scholar]
  6. Duara R., Barker W. W., Lopez-Alberola R., Loewenstein D. A., Grau L. B., Gilchrist D., Sevush S., St George-Hyslop S. Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. Neurology. 1996 Jun;46(6):1575–1579. doi: 10.1212/wnl.46.6.1575. [DOI] [PubMed] [Google Scholar]
  7. Evans R. T., Wardell J. On the identification and frequency of the J and K cholinesterase phenotypes in a Caucasian population. J Med Genet. 1984 Apr;21(2):99–102. doi: 10.1136/jmg.21.2.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  9. Guillozet A. L., Smiley J. F., Mash D. C., Mesulam M. M. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol. 1997 Dec;42(6):909–918. doi: 10.1002/ana.410420613. [DOI] [PubMed] [Google Scholar]
  10. Hiltunen M., Mannermaa A., Helisalmi S., Koivisto A., Lehtovirta M., Ryynänen M., Riekkinen P., Sr, Soininen H. Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients. Neurosci Lett. 1998 Jun 26;250(1):69–71. doi: 10.1016/s0304-3940(98)00453-4. [DOI] [PubMed] [Google Scholar]
  11. Hosseini J., Firuzian F., Feely J. Ethnic differences in the frequency distribution of serum cholinesterase activity. Ir J Med Sci. 1997 Jan-Mar;166(1):10–12. doi: 10.1007/BF02939767. [DOI] [PubMed] [Google Scholar]
  12. Jensen F. S., Nielsen L. R., Schwartz M. Detection of the plasma cholinesterase K variant by PCR using an amplification-created restriction site. Hum Hered. 1996 Jan-Feb;46(1):26–31. doi: 10.1159/000154321. [DOI] [PubMed] [Google Scholar]
  13. Kehoe P. G., Williams H., Holmans P., Wilcock G., Cairns N. J., Neal J., Owen M. J. The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease. J Med Genet. 1998 Dec;35(12):1034–1035. doi: 10.1136/jmg.35.12.1034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Khachaturian Z. S. Diagnosis of Alzheimer's disease. Arch Neurol. 1985 Nov;42(11):1097–1105. doi: 10.1001/archneur.1985.04060100083029. [DOI] [PubMed] [Google Scholar]
  15. Lehmann D. J., Johnston C., Smith A. D. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet. 1997 Oct;6(11):1933–1936. doi: 10.1093/hmg/6.11.1933. [DOI] [PubMed] [Google Scholar]
  16. McIlroy S. P., Dynan K. B., McGleenon B. M., Lawson J. T., Passmore A. P. Cathepsin D gene exon 2 polymorphism and sporadic Alzheimer's disease. Neurosci Lett. 1999 Oct 1;273(2):140–141. doi: 10.1016/s0304-3940(99)00635-7. [DOI] [PubMed] [Google Scholar]
  17. McIlroy S. P., Vahidassr M. D., Savage D. A., Patterson C. C., Lawson J. T., Passmore A. P. Risk of Alzheimer's disease is associated with a very low-density lipoprotein receptor genotype in Northern Ireland. Am J Med Genet. 1999 Apr 16;88(2):140–144. doi: 10.1002/(sici)1096-8628(19990416)88:2<140::aid-ajmg9>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  18. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  19. Miller S. A., Dykes D. D., Polesky H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215–1215. doi: 10.1093/nar/16.3.1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Perry E. K. The cholinergic system in old age and Alzheimer's disease. Age Ageing. 1980 Feb;9(1):1–8. doi: 10.1093/ageing/9.1.1. [DOI] [PubMed] [Google Scholar]
  21. Scacchi R., De Bernardini L., Mantuano E., Donini L. M., Vilardo T., Corbo R. M. Apolipoprotein E (APOE) allele frequencies in late-onset sporadic Alzheimer's disease (AD), mixed dementia and vascular dementia: lack of association of epsilon 4 allele with AD in Italian octogenarian patients. Neurosci Lett. 1995 Dec 15;201(3):231–234. doi: 10.1016/0304-3940(95)12190-0. [DOI] [PubMed] [Google Scholar]
  22. Smith M. A. Alzheimer disease. Int Rev Neurobiol. 1998;42:1–54. doi: 10.1016/s0074-7742(08)60607-8. [DOI] [PubMed] [Google Scholar]
  23. Strittmatter W. J., Roses A. D. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A. 1995 May 23;92(11):4725–4727. doi: 10.1073/pnas.92.11.4725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Whittaker M., Britten J. J. Plasma cholinesterase variants. Family studies of the E1k gene. Hum Hered. 1985;35(6):364–368. doi: 10.1159/000153581. [DOI] [PubMed] [Google Scholar]
  25. Wiebusch H., Poirier J., Sévigny P., Schappert K. Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet. 1999 Feb;104(2):158–163. doi: 10.1007/s004390050929. [DOI] [PubMed] [Google Scholar]
  26. Zschocke J., Mallory J. P., Eiken H. G., Nevin N. C. Phenylketonuria and the peoples of Northern Ireland. Hum Genet. 1997 Aug;100(2):189–194. doi: 10.1007/s004390050488. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES